Biopsy Devices Market Growth Driven by Innovation and Minimally Invasive Diagnostics

The biopsy devices market is witnessing notable growth as healthcare providers increasingly focus on precise, timely, and minimally invasive diagnosis. Biopsy devices are medical instruments designed to obtain tissue or cellular samples for pathological examination and remain essential in diagnosing cancer and several other medical conditions. According to DelveInsight, the global market was valued at USD 5,813.16 million in 2024 and is anticipated to reach USD 10,812.77 million by 2032, registering a CAGR of 8.09% from 2025 to 2032. Growing cancer prevalence, technological progress, increasing preference for minimally invasive procedures, and continued product innovation are among the key factors supporting market expansion.

Biopsy Devices Market Growth Supported by the Rising Cancer Burden

The growing worldwide incidence of cancer continues to strengthen the demand for biopsy technologies. Diseases such as breast, lung, prostate, and colorectal cancer often require tissue sampling to confirm diagnosis, determine disease characteristics, and guide treatment decisions. DelveInsight estimates that global breast cancer incidence stood at approximately 2,296,841 cases in 2022 and may rise to 3,364,291 cases by 2045. Increasing emphasis on screening, early diagnosis, and personalized medicine is therefore creating greater demand for dependable tissue collection technologies.

Beyond oncology, biopsy procedures are increasingly used to investigate inflammatory, infectious, gastrointestinal, and other disorders. As diagnostic pathways become more advanced, clinicians are seeking biopsy systems capable of collecting representative samples with greater accuracy while reducing discomfort and procedural risks. This expanding clinical application is supporting demand across hospitals, diagnostic laboratories, imaging centers, and ambulatory healthcare facilities.

Biopsy Devices Market Advances Through Emerging Technologies

Technological innovation is significantly changing biopsy procedures by improving targeting accuracy, procedural efficiency, and patient safety. Modern biopsy platforms are increasingly incorporating image guidance, vacuum-assisted mechanisms, robotics, artificial intelligence, automation, and digital pathology. These technologies can help clinicians obtain high-quality tissue samples while reducing unnecessary tissue trauma and improving workflow efficiency.

The development of smarter biopsy technologies is also creating new opportunities within the sector. Advanced systems increasingly combine sensors, imaging technologies, automation, and data-driven tools to support tissue acquisition. Robotic platforms can assist physicians with accurate needle placement, while AI-enabled pathology applications can help analyze biopsy specimens. Such innovations are expanding the capabilities of biopsy procedures and encouraging healthcare facilities to invest in technologically advanced diagnostic systems.

Biopsy Devices Market Demand Remains Strong in Breast Biopsy Applications

Breast biopsy represents one of the most important application areas because of the continued burden of breast cancer and the expansion of screening programs. The increasing use of mammography and ultrasound examinations has resulted in the identification of more suspicious lesions requiring tissue confirmation. DelveInsight estimates that breast biopsy represented nearly 30% of the global market share in 2024.

Core needle biopsy, fine-needle aspiration, and vacuum-assisted biopsy are gaining acceptance because they can provide diagnostically useful samples while generally requiring less invasive approaches than traditional surgical biopsy. In May 2024, Hologic introduced a disposable 7-gauge breast biopsy needle for its Brevera breast biopsy system in Europe, adding to its existing 9-gauge offering. Such product developments reflect the industry's continued focus on improving sample collection, procedural flexibility, and patient experience.

Biopsy Devices Market Growth Led by Needle-Based Products

Needle-based biopsy devices are expected to continue representing a significant product category. According to DelveInsight, needle-based instruments accounted for approximately 39% of the market in 2024. Core biopsy needles, fine-needle aspiration devices, and vacuum-assisted biopsy needles are widely used because they provide effective tissue sampling through comparatively minimally invasive procedures.

These products can be utilized to collect tissue from several organs, including the breast, lung, prostate, liver, and kidney. Their compatibility with imaging modalities such as ultrasound, computed tomography, and magnetic resonance imaging can improve lesion targeting and potentially reduce sampling inaccuracies. Ongoing improvements in needle construction, ergonomics, automation, and disposable components are expected to further support adoption across diverse clinical applications.

Biopsy Devices Market Expansion Creates Regional Opportunities

North America is expected to retain a substantial share of the global market, supported by advanced healthcare infrastructure, a high cancer burden, sophisticated diagnostic capabilities, reimbursement availability, and significant investment in research and development. DelveInsight estimates that North America accounted for approximately 41% of the global market in 2024.

The U.S. market is benefiting from the growing utilization of image-guided biopsy procedures, robotic systems, vacuum-assisted technologies, and AI-supported diagnostic workflows. Extensive cancer screening programs and the presence of established medical device manufacturers are also contributing to the availability and adoption of advanced biopsy solutions.

Meanwhile, Asia-Pacific is emerging as another important area of opportunity. Increasing healthcare expenditure, improvements in diagnostic infrastructure, growing awareness of cancer screening, and government-led healthcare initiatives are supporting the adoption of biopsy technologies. China, India, and Japan are among the markets offering opportunities as healthcare accessibility improves and minimally invasive diagnostic procedures become more widely utilized.

Biopsy Devices Market Opportunities Expand Across India and Asia-Pacific

The Indian market is expected to benefit from ongoing improvements in healthcare infrastructure and greater awareness surrounding early cancer diagnosis. Investments in hospitals, diagnostic centers, imaging facilities, and specialized healthcare services are helping improve access to tissue sampling procedures. Increasing healthcare expenditure and wider adoption of image-guided diagnostic approaches are also creating opportunities for technologically advanced biopsy systems.

Across the broader Asia-Pacific region, a large patient population, increasing disease burden, expanding medical infrastructure, and improving access to advanced diagnostic technologies are expected to sustain long-term demand. International manufacturers are also increasing their regional presence through product introductions, strategic collaborations, and technological developments, contributing to the evolution of the diagnostic ecosystem.

Biopsy Devices Market Outlook Reflects Continued Innovation

The biopsy devices market size is expected to expand considerably through 2032 as demand for accurate tissue diagnosis and minimally invasive procedures continues to rise. Nevertheless, several challenges could influence adoption, including the high cost of sophisticated robotic and image-guided systems, regulatory complexities, patient concerns surrounding biopsy procedures, and shortages of appropriately trained healthcare professionals.

Competition from liquid biopsy and advanced imaging techniques may also affect the evolution of conventional tissue biopsy approaches. At the same time, industry development is increasingly focused on artificial intelligence, digital pathology, robotic assistance, vacuum-assisted systems, and smart needle technologies.

Recent industry developments further highlight this technological transition. Biobot Surgical's Mona Lisa 2.0 robotic system received CE certification in January 2025, while other developments have involved AI-supported prostate pathology and robotic needle-delivery technologies. These advancements demonstrate the industry's broader movement toward precision diagnostics, automation, and digitally integrated biopsy workflows.

Biopsy Devices Market Future Direction

The global biopsy devices industry is positioned for continued development as healthcare systems prioritize earlier diagnosis, accurate tissue assessment, and less invasive procedures. Advances in robotics, artificial intelligence, imaging, digital pathology, and tissue-sampling technologies are reshaping diagnostic workflows and expanding the capabilities of biopsy procedures. North America continues to benefit from established healthcare infrastructure, while Asia-Pacific presents opportunities linked to improving healthcare access and diagnostic capabilities. Continued technological innovation, product development, and broader adoption of minimally invasive diagnostic approaches are likely to remain important factors shaping the industry's future.

Latest Reports by DelveInsight:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Search This Blog

Delveinsight Report